Maria E Rodriguez-Ruiz
Overview
Explore the profile of Maria E Rodriguez-Ruiz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
3470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gambardella V, Ong M, Rodriguez-Ruiz M, Machiels J, Sanmamed M, Galvao V, et al.
Cancer Res Commun
. 2025 Feb;
5(3):422-432.
PMID: 39983024
Purpose: Therapeutic depletion of immunosuppressive regulatory T cells (Treg) may overcome resistance to cancer immunotherapies. RG6292 is an anti-CD25 antibody that preferentially depletes Tregs while preserving effector T-cell functions in...
2.
Garate-Soraluze E, Serrano-Mendioroz I, Fernandez-Rubio L, de Andrea C, Barrio-Alonso C, Herrero C, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39933836
Background: Ionizing radiation (IR) is a double-edged sword for immunotherapy as it may have both immunosuppressive and immunostimulatory effects. The biological effects of IR on the tumor microenvironment (TME) are...
3.
Luri-Rey C, Teijeira A, Wculek S, de Andrea C, Herrero C, Lopez-Janeiro A, et al.
Nat Rev Cancer
. 2025 Jan;
PMID: 39881005
Cytotoxic T cell immune responses against cancer crucially depend on the ability of a subtype of professional antigen-presenting cells termed conventional type 1 dendritic cells (cDC1s) to cross-present antigens. Cross-presentation...
4.
de Dios O, Ramirez-Gonzalez M, Gomez-Soria I, Segura-Collar B, Manosalva J, Megias D, et al.
J Immunother Cancer
. 2024 Aug;
12(8).
PMID: 39214651
Background: Activating and inhibitory receptors of natural killer (NK) cells such as NKp, NKG2, or CLEC are highly relevant to cold tumors including glioblastoma (GBM). Here, we aimed to characterize...
5.
Segal N, Melero I, Moreno V, Steeghs N, Marabelle A, Rohrberg K, et al.
Nat Commun
. 2024 May;
15(1):4091.
PMID: 38750034
Cibisatamab is a bispecific antibody-based construct targeting carcinoembryonic antigen (CEA) on tumour cells and CD3 epsilon chain as a T-cell engager. Here we evaluated cibisatamab for advanced CEA-positive solid tumours...
6.
Steeghs N, Gomez-Roca C, Rohrberg K, Mau-Sorensen M, Robbrecht D, Tabernero J, et al.
Clin Cancer Res
. 2024 Apr;
30(13):2693-2701.
PMID: 38630781
Purpose: Simlukafusp alfa [fibroblast activation protein α-targeted IL2 variant (FAP-IL2v)], a tumor-targeted immunocytokine, comprising an IL2 variant moiety with abolished CD25 binding fused to human IgG1, is directed against fibroblast...
7.
Teijeira A, Garasa S, Ochoa M, Sanchez-Gregorio S, Gomis G, Luri-Rey C, et al.
Clin Cancer Res
. 2024 Apr;
30(18):4131-4142.
PMID: 38630754
Purpose: Patients with cancer frequently undergo radiotherapy in their clinical management with unintended irradiation of blood vessels and copiously irrigated organs in which polymorphonuclear leukocytes circulate. Following the observation that...
8.
Garate-Soraluze E, Marco-Sanz J, Serrano-Mendioroz I, Marrodan L, Fernandez-Rubio L, Labiano S, et al.
Methods Cell Biol
. 2024 Mar;
185:99-113.
PMID: 38556454
Radiotherapy is a crucial treatment modality for cancer patients, with approximately 60% of individuals undergoing ionizing radiation as part of their disease management. In recent years, there has been a...
9.
Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz M, et al.
Mol Cancer
. 2024 Mar;
23(1):61.
PMID: 38519913
Background: Immuno-radiotherapy may improve outcomes for patients with advanced solid tumors, although optimized combination modalities remain unclear. Here, we report the colorectal (CRC) cohort analysis from the SABR-PDL1 trial that...
10.
Alvarez M, Molina C, Garasa S, Ochoa M, Rodriguez-Ruiz M, Gomis G, et al.
Oncoimmunology
. 2023 Apr;
12(1):2197370.
PMID: 37035637
BO-112 is a poly I:C-based viral mimetic that exerts anti-tumor efficacy when intratumorally delivered in mouse models. Intratumoral BO-112 synergizes in mice with systemic anti-PD-1 mAbs and this combination has...